Track market-moving stories before they get noisy

PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on October 14, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 32 new employees in restricted stock units for an aggregate of 57,853 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically significant 18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation, and diuretic intensification versus tafamidis (HR 0.82; 95% CI 0.73-0.93; p<0.01)

- Early separation of the composite curves was noted within one month in this contemporary cohort of patients from 2025, with consistent results across unadjusted, matched, and biomarker-adjusted analyses

- Acoramidis was associated with significant reductions in hospitalization, among the outcomes that matter most to people living with ATTR-CM, with a 27% lower risk of cardiovascular hospitalization, 27% lower risk of heart failure hospitalization, and 25% lower risk of all-cause hospitalization as compared to tafamidis (all p<0.001) 

- These findings replicate the earlier Wright et al. Komodo claims analysis published in Cardiology and Therapy, in which acoramidis was associated with a 34% reduction in clinical worsening events versus tafamidis (p=0.046), making this the second real-world comparative effectiveness analysis, and the first in electronic health records, to favor acoramidis, supporting the reproducibility of the benefit

- ATTRibute-CM data also presented at HFSA underscore the importance of hospitalization reduction: mortality risk approximately doubled after a single cardiovascular hospitalization and quadrupled after two or more, making hospitalization prevention a central treatment goal in ATTR-CM

- Together, these data have the potential to inform the use of acoramidis as the stabilizer of choice, both in newly diagnosed patients and in those on other disease-modifying agents

PALO ALTO, Calif., Oct. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced that new, independent and contemporary real-world evidence as well as Phase 3 ATTRibute-CM sub-analyses of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2026 in Phoenix, Arizona. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

"In a prior real-world claims analysis, acoramidis was associated with fewer diuretic intensification events, suggesting the possibility of greater clinical stability on acoramidis, but this obviously needed to be interpreted with caution. This new, larger, electronic health record study of nearly 2,700 individuals with ATTR-CM with longer follow-up and more granular data is better able to address the question, and shows a similar signal, with a significant difference in rates of cardiovascular or heart failure hospitalizations favoring acoramidis compared to tafamidis, with approximately one quarter lower risk of events," said David Lanfear, M.D., M.S., Chief Scientific Officer, Vice President of Research at Henry Ford Health, U.S. "While electronic health record studies have well-recognized limitations, these data allow us to see how these therapies perform outside of a clinical trial, across a diverse and contemporary patient population. Moreover, there appears to be some consistency of findings across data sources and endpoints, supporting validity. Additional investigations to replicate and extend these findings are warranted."

In a retrospective analysis conducted and presented by Dr. Lanfear, individuals with ATTR-CM newly initiating acoramidis had lower rates of adverse cardiac outcomes than individuals newly initiating tafamidis. The study leveraged data from Epic COSMOS, the largest U.S. electronic health record database, with over 300 million patients. This dataset includes detailed, anonymized clinical records captured in the course of routine patient care, such as laboratory values and medication records. After matching, 910 acoramidis-treated and 1,774 tafamidis-treated individuals were included, with similar baseline characteristics across treatment groups. Key findings included:

The composite endpoint of death, all-cause hospitalization, new-onset atrial fibrillation, or diuretic intensification was significantly lower with acoramidis across all three analyses: unadjusted (HR 0.82; 95% CI 0.72-0.90; p<0.001), primary (18% lower risk; HR 0.82; 95% CI 0.73-0.93; p<0.01), and a sensitivity analysis adjusting for a combined standardized NT-proBNP and BNP variable where available (HR 0.84; 95% CI 0.72-0.97; p=0.02)Acoramidis-treated individuals had statistically significantly lower rates of hospitalization than tafamidis-treated individuals, including a 27% lower risk of cardiovascular hospitalization (HR 0.73; 95% CI 0.62-0.86; p<0.001), a 27% lower risk of heart failure hospitalization (HR 0.73; 95% CI 0.62-0.87; p<0.001), and a 25% lower risk of all-cause hospitalization (HR 0.75; 95% CI 0.64-0.88; p<0.001)Diuretic intensification, an early marker of disease progression, was 17% lower with acoramidis (HR 0.83; 95% CI 0.71-0.95; p<0.01). Diuretic intensification was defined as use of parenteral loop diuretics, initiation or dose-equivalent escalation of oral loop diuretics, or use of a thiazide-like diureticDifferences in death (HR 0.85; 95% CI 0.62-1.20; p=0.34) and new-onset atrial fibrillation (HR 0.88; 95% CI 0.68-1.13; p=0.31) numerically favored acoramidis, consistent with the composite, but did not reach statistical significance, reflecting lower event counts and limited duration of follow-up for these longer-term endpoints. These endpoints will be reassessed as the cohort maturesKaplan-Meier time-to-event curves for the composite endpoint showed early and sustained separation between treatment groups over follow-up (p=0.0014)The consistency of the treatment effect across unadjusted, matched, and biomarker-adjusted analyses and across multiple clinical outcomes supports the robustness of the observed difference These findings in electronic health record data replicate and expand on the results of the first peer-reviewed, claims-based real-world comparative effectiveness study of TTR stabilizers in ATTR-CM, in which acoramidis was associated with a 34% reduction in a composite of clinical worsening events (diuretic intensification, heart failure hospitalization, and mortality) versus tafamidis (p=0.046), supporting the reproducibility of the observed benefit across independent data sources and data types.

As with all observational studies, there are inherent limitations. Although propensity-score matching balanced patient baseline characteristics and results remained consistent across both unweighted and sensitivity analyses, the possibility of residual confounding cannot be fully excluded. Follow-up was relatively short due to recent approval of acoramidis, which limited the number of events available to assess less frequent outcomes, such as mortality. These factors would not be expected to affect one treatment group differently than the other, and the consistency of results across multiple endpoints and in multiple studies supports the robustness of the findings. As data continue to mature, additional analyses with longer follow-up periods will be shared. The full results of this analysis are currently under peer-review by a journal.

Three additional analyses presented at HFSA ASM 2026 continued to reinforce the acoramidis narrative, reaffirming the importance of reducing cardiovascular-related hospitalizations (CVH) in ATTR-CM, the differentiated cardiorenal impact of acoramidis, and the benefit of acoramidis within variant ATTR-CM patients:

Cardiovascular-related hospitalizations associated with higher risk of mortality: Association Between the Burden of CVH and All-Cause Mortality (ACM) in Transthyretin Amyloid Cardiomyopathy: Insights from ATTRibute-CM, presented by Quan Bui, M.D. of UC San Diego Health, U.S. In this post hoc analysis of ATTRibute-CM (pooled treatment groups; N=611), fewer than half of participants who experienced two or more cardiovascular-related hospitalizations were alive at 30 months. Survival fell from 86.7% in participants with no CVH events to 68.4% with one and 47.7% with two or more (log-rank p<0.0001)Mortality risk approximately doubled after a single hospitalization and quadrupled after two or more, establishing CVH burden as a marker of subsequent mortality risk and reinforcing hospitalization prevention as a clinically meaningful treatment goal in ATTR-CMAcoramidis reduced the annualized frequency of CVH by 50% through Month 30 versus placebo (p < 0.0001), with Kaplan-Meier curves for time to first CVH separating from Month 3 Unique cardiorenal impact of acoramidis: Early eGFR Dip Following Acoramidis Initiation is Associated With Reduced Risk of Mortality and Recurrent Cardiovascular-Related Hospitalizations in ATTR-CM, presented by Ahmad Masri, M.D., M.S. of Oregon Health & Science University, U.S. In the ATTRibute-CM study, acoramidis-treated participants with a greater Day 28 eGFR dip following treatment initiation were associated with a significantly reduced risk of mortality or recurrent CVH versus placebo, with no clinically concerning changes observed in laboratory parameters or blood pressureThese findings provide additional context for the reported association between greater early eGFR decline and improved first CVH outcomes with acoramidis, and build upon the 42% reduction in recurrent CVH/ACM previously demonstrated with acoramidis over placebo in ATTRibute-CMThese results build upon analyses previously published in Circulation: Heart Failure; details on results can be found here Acoramidis benefit in p.Val142Ile variant patients: Acoramidis Preserves Functional Capacity and Quality of Life in p.Val142Ile Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM, presented by Lily Stern, M.D. of Cedars-Sinai Heart Institute, U.S. In this post hoc analysis of 35 ATTRibute-CM participants with the p.Val142Ile variant (acoramidis, n = 23; placebo, n = 12), acoramidis significantly attenuated 30-month declines in heart failure-related health status and quality of life versus placebo: differences of 23.3 points in KCCQ-OS score (p = 0.005), 25.8 points in EQ VAS score (p = 0.003), and 0.26 in EQ-5D-5L index score (p = 0.018), each several-fold above published thresholds for clinically meaningful change.Decline in 6-minute walk distance was numerically smaller with acoramidis (LSM difference: 67.2 m; p = 0.136)These findings complement the previously reported 69% reduction in the risk of all-cause mortality or first cardiovascular-related hospitalization with acoramidis through Month 30 in this subgroup
In addition to the two rapid-fire oral presentations, one oral presentation, and one poster presentation highlighted, there was one additional rapid-fire oral presentation and five additional poster presentations along with four encore poster presentations shared at HFSA ASM 2026, which included:

Ratio of Serum Transthyretin to NT-proBNP is a Novel Prognostic Measure for Transthyretin Amyloid Cardiomyopathy: Insights from ATTRibute-CM, presented by James L. Januzzi, M.D. of Massachusetts General Hospital, U.S. and simultaneously published in JACC: Heart Failure
In ATTR-CM, early acoramidis-mediated sTTR increases were associated with later NT-proBNP decreases. The Day 28 sTTR to Month 12 NT-proBNP ratio, integrating early pharmacodynamic response with downstream cardiac stress, is a prognostic biomarker of clinical risk in ATTR-CM Falls and Fractures Drive Increased Hospitalizations and Costs in Patients with Transthyretin Amyloid Cardiomyopathy Compared with Controls, presented by Nitasha Sarswat, M.D. of University of Chicago, U.S. ATTR-CM was associated with increased falls and fall-related consequences, including fractures, bleeding after a fall, discontinuation of oral anticoagulant use, and related hospitalizations and costs, compared with matched heart failure (HF) and non-HF controls, consistent with substantial disease burden beyond cardiac manifestations and with higher healthcare resource utilization Evaluating the Long-Term Effects of Acoramidis on Cardiac Function, Structure, and Amyloid Burden in Transthyretin Amyloid Cardiomyopathy: ASCEND-ATTR, presented by Ahmad Masri, M.D., M.S. of Oregon Health & Science University, U.S. ASCEND-ATTR will determine whether long-term transthyretin stabilization is associated with sustained improvement in myocardial structure, function, and amyloid burden. By integrating serial CMR and echocardiography, the study aims to provide mechanistic insights into cardiac remodeling during treatment and help define imaging biomarkers of therapeutic response Real-World Burden of Transthyretin Amyloid Cardiomyopathy Disease and Outcomes in Patients on Tafamidis Prior to Initiating Acoramidis, presented by Richard Wright, M.D. of Pacific Heart Institute, U.S. Nearly half of patients receiving tafamidis exhibited markers of ATTR-CM clinical worsening within the 6 months preceding acoramidis initiation. This burden appears higher than previously reported real-world disease progression rates after tafamidis initiation and warrants further study. Future research should evaluate drivers of switching therapy and outcomes after transitioning to acoramidis Acoramidis Reduces Risk of Cardiovascular-related Mortality and Hospitalization in Women with Transthyretin Amyloid Cardiomyopathy, presented by Margot Davis, M.D. of University of British Columbia, Vancouver, Canada
Among women enrolled in ATTRibute-CM, who entered the trial older and with a more advanced clinical phenotype than men, acoramidis reduced the risk of cardiovascular mortality or first cardiovascular-related hospitalization through Month 30 and attenuated the rise in NT-proBNP versus placebo. Treatment effects in women aligned with the overall population, with no significant treatment-by-sex interaction. This may represent the first reported analysis from a phase 3 ATTR-CM trial to show a nominally statistically significant treatment effect for this endpoint among women. While the small number of women enrolled limits precision, these findings support the efficacy of acoramidis in women and underscore the need for adequately powered, sex-informed evidence in ATTR-CM
Effect of Acoramidis on Heart Failure-Related Health Status Before and After Cardiovascular-Related Hospitalization: Insights from ATTRibute-CM, presented by Ahmad Masri, M.D., M.S. of Oregon Health & Science University, U.S. Worsening KCCQ-OS precedes CVH and may serve as an early indicator of an adverse outcome in patients with ATTR-CM. Following a CVH event, acoramidis was associated with recovery of health status versus continued decline observed with placebo, suggesting a beneficial effect on post-CVH health status trajectory Acoramidis is approved as Attruby® by the U.S. FDA and is approved as BEYONTTRA® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, and the Brazilian Health Regulatory Agency (ANVISA) with all labels specifying near-complete stabilization of TTR.

Additional data on the benefit of Attruby for individuals with ATTR-CM is planned for future medical meetings.

About Attruby® (acoramidis)

INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions, or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the real-world and ATTRibute-CM data regarding acoramidis, including the potential for the findings to inform treatment selection for newly diagnosed patients and patients currently receiving other disease-modifying therapies and to support switching individuals to acoramidis; the potential reproducibility, durability and broader clinical significance of observed benefits associated with acoramidis across independent data sources, including with respect to cardiovascular and heart failure hospitalizations, clinical stability and other outcomes; the potential clinical and therapeutic implications of the ATTRibute-CM analyses, including with respect to cardiovascular hospitalization, cardiorenal outcomes, biomarkers, health status and outcomes in patient subgroups; the design, conduct and anticipated findings of ASCEND-ATTR, including whether long-term TTR stabilization is associated with sustained improvement in myocardial structure, function and amyloid burden and the potential to identify imaging biomarkers of therapeutic response; and BridgeBio’s plans and expectations regarding additional analyses, longer-term follow-up, future research, publications and presentations of data regarding acoramidis. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the risk that results from retrospective, observational, real-world evidence studies, including studies based on electronic health records or administrative claims data, may be subject to confounding, selection bias, residual bias, incomplete or inaccurate data, limited follow-up or other limitations and may not be predictive of future clinical outcomes or treatment effects; that observed associations and differences between acoramidis and tafamidis may not be replicated in additional analyses, independent studies or longer-term data or may not translate into improved long-term clinical outcomes; that results from post hoc analyses, subgroup analyses or other analyses may not be predictive of future clinical outcomes or treatment effects and may not be replicated in additional analyses or studies; that observed effects on cardiovascular hospitalizations, cardiorenal outcomes, biomarkers, health status or outcomes in patient subgroups may not be replicated or translate into meaningful long-term clinical benefit; that the findings may not meaningfully inform treatment selection or support switching patients to acoramidis; that mechanistic or prognostic interpretations of observed data, including potential relationships among TTR stabilization, cardiac remodeling, cardiorenal effects, biomarkers and clinical outcomes, may not be borne out by further analyses or additional data; that ASCEND-ATTR may not demonstrate sustained improvement in myocardial structure, function or amyloid burden or identify useful imaging biomarkers of therapeutic response; that additional analyses, longer-term follow-up or future research may yield results that differ from or do not confirm the findings described in this press release; that plans or timing for future analyses, medical meeting presentations or scientific publications may change; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected]
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
[email protected]

 | Source: BridgeBio Pharma, Inc.

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) will be shared at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place in Boston, Massachusetts on October 9-12, 2026.

BridgeBio will present the effects of encaleret on patient-reported outcomes and on bone turnover from the Phase 3 CALIBRATE trial. In partnership with the HypoPARAthyroidism Association, BridgeBio will also share findings from regional family cascade genetic testing events that evaluated a proband-initiated model designed to bring no-cost genetic testing and counseling directly to at-risk relatives in their home region.

BridgeBio will also have a poster featuring data showing a lack of peripheral FGFR1 inhibition at clinically relevant infigratinib exposures, supporting the safety profile observed in children with achondroplasia in the PROPEL clinical program.

ADH1 Oral Presentations:
Encaleret Restores Mineral Homeostasis and Increases Bone Turnover in Autosomal Dominant Hypocalcemia Type 1 (ADH1): 24-Week Results from Phase 3 CALIBRATE Trial
Presenter: Erik A. Imel, M.D., Indiana University School of Medicine
Date: Sunday, October 11 at 11:42 am EDT

Participant-Reported Changes in Symptoms and Treatment Experience with Encaleret in Autosomal Dominant Hypocalcemia Type 1: 24-Week Findings from the Phase 3 CALIBRATE Trial
Presenter: Steven W. Ing, M.D., Ohio State University Wexner Medical Center
Date: Sunday, October 11 at 11:54 am EDT

ADH1 Posters:
Baseline Symptom Burden and Impact on Daily Functioning in Autosomal Dominant Hypocalcemia Type 1: Exit Interview Findings from the Phase 3 CALIBRATE Trial
Presenter: Susan Martin, MSPH, RTI Health Solutions
Date: Saturday, October 10 at 2:00 pm EDT

Family Cascade Genetic Testing for Autosomal Dominant Hypocalcemia Type 1: A Multi-Stakeholder Regional Event Model
Presenter: Mark Warren, M.D., Physicians East, Greenville, NC
Date: Saturday, October 10 at 2:00 pm EDT

Achondroplasia Poster:
Lack of Peripheral FGFR1 Inhibition at Clinically Relevant Infigratinib Exposures Supports the Safety Profile Observed in Children with Achondroplasia
Presenter: Bhavik Shah, BridgeBio Skeletal Dysplasias
Date: Sunday, October 11 at 2:00 pm EDT

About Autosomal Dominant Hypocalcemia Type 1 (ADH1)
ADH1 is a common form of genetic hypoparathyroidism caused by gain-of-function variants in the calcium-sensing receptor gene (CASR). The calcium-sensing receptor (CaSR) constantly monitors and balances blood calcium levels by regulating parathyroid hormone secretion and calcium reabsorption in the kidneys. Individuals with ADH1 typically experience hypocalcemia, hypercalciuria, and inappropriately low levels of PTH. Symptoms of hypocalcemia may include severe muscle cramps, muscle spasms (tetany), a burning or prickling sensation in the hands or feet (paresthesia), brain fog, fatigue, and seizures. Hypercalciuria may result in kidney calcification (nephrocalcinosis), kidney stones (nephrolithiasis), and kidney failure.

About Encaleret
Encaleret is an investigational, orally administered small molecule under investigation to treat ADH1 and chronic hypoparathyroidism that is designed to selectively negatively modulate the calcium-sensing receptor. Encaleret has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation in the U.S., European Union, and Japan.

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected]
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
[email protected]

- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide

PALO ALTO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company” or “BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on genetic diseases, today announced a nationwide education effort with community partners to increase awareness of transthyretin amyloid cardiomyopathy, also called ATTR cardiac amyloidosis (ATTR-CM). ATTR-CM is an underrecognized cause of heart failure that occurs when TTR, a protein that plays an essential role in the transport of vitamin A and thyroxine, becomes unstable, breaks down and builds up in the heart, causing it to become thicker and stiffer and making it harder to pump blood effectively. Because symptoms may resemble more common heart conditions or be dismissed as normal aging, ATTR-CM can be overlooked or identified later in the disease journey.

The effort will begin with an October 6 YouTube premiere and continue through community conversations and educational programming leading up to World Amyloidosis Day on October 26.

The premiere features a candid conversation on Black men’s heart health and ATTR-CM moderated by veteran broadcaster, Sway Calloway. The panel includes sports executive, author, philanthropist and ATTR-CM advocate, Howard “H” White; Albert J. Hicks III, M.D., MPH, Director of Cardiopulmonary Care and Heart/Lung Transplant at Integris Baptist Medical Center in Oklahoma; and Hip Hop Public Health (HHPH) Founding Artist and Founder, Doug E. Fresh and HHPH Founder and Board Chair, Olajide Williams, M.D., M.S., who serve as Community and Health Education Partners for the initiative. The program will premiere October 6 at 6:00 pm EDT at HowardWhiteStory.com/premiere.

The nationwide effort is supported by community partners including the Association of Black Cardiologists (ABC), the National Minority Quality Forum (NMQF), 100 Black Men of the Bay Area, Inc. and the National Medical Association (NMA). Partners will host or support viewings and related educational programming at 40 locations nationwide, including Atlanta, Chicago, Houston, Los Angeles, New York, Oakland, and Washington D.C.

“ATTR-CM deserves greater attention as part of the cardiovascular health conversation, particularly for Black Americans who may be at increased risk. We’re proud to support BridgeBio in helping patients, families and healthcare professionals recognize when there may be more to a heart failure diagnosis,” said Kevin Kwaku, M.D., Ph.D., President of the Association of Black Cardiologists.

“Approximately 1 in 25 Black Americans carries a genetic variant associated with ATTR-CM, and too often the diagnosis comes only after the heart has already been significantly affected,” said Uma Sinha, Ph.D., Chief Scientific Officer at BridgeBio. “Our understanding of this progressive disease has moved faster than awareness of it. Shortness of breath, fatigue, and carpal tunnel in both wrists can be written off as aging or as a more common form of heart failure, and years can pass before anyone names the real cause. Putting clinicians, cultural leaders and Howard ‘H’ White’s lived experience in the same room, alongside partners rooted in these communities, is how we close this gap.”

At the center of the conversation is White, who is living with ATTR-CM and founded the Howard H. White Center for Cardiac Amyloidosis. Drawing on his own journey from symptoms to diagnosis, he has become a prominent voice for recognizing changes in one’s health, speaking up and advocating for answers.

As the Community and Health Education Partners, Dr. Williams and Doug E. Fresh reinforced the importance of moving health conversations from awareness to action, particularly through trusted voices, culture and community.

“At Hip Hop Public Health, we know that people are more likely to engage with health information when it is relevant to their lives and delivered through voices and cultural touchpoints they trust. Our goal is to make these conversations accessible and actionable, so people feel empowered to recognize changes in their health, ask questions and advocate for themselves and their families,” said Dr. Williams.

ATTR-CM exists in two forms: wild-type disease associated with aging and hereditary, or variant, disease passed through families. Certain variants are more commonly carried by people of African ancestry. Approximately 1 in 25 Black Americans in the United States carries the V142I, also known as V122I, variant associated with ATTR-CM, although not everyone who carries the variant will develop the disease.1–3

“ATTR-CM can hide in plain sight because its symptoms often mirror heart failure we see every day. For Black patients, particularly those with ancestry-linked risk, knowing when to look beyond the familiar diagnosis can change the course of the disease,” said Dr. Hicks. 

The discussion also examines broader cardiovascular disparities affecting Black Americans and why greater awareness, earlier recognition and conversations with healthcare providers matter.

Watch the premiere on October 6 at 6:00 pm EDT at HowardWhiteStory.com/premiere.

Learn more about ATTR-CM and hear Howard “H” White’s story at HowardWhiteStory.com.

About Hip Hop Public Health
Hip Hop Public Health (HHPH) is a 501(c)(3) nonprofit organization that uses the power of music, culture and science to make health information accessible, relevant and actionable. Founded by Dr. Olajide Williams and Doug E. Fresh, HHPH develops evidence-based educational resources and community partnerships that advance health literacy, disease prevention and health equity. HHPH serves as the Community & Health Education Partner for this initiative. For more information, visit hhph.org.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube and TikTok.

BridgeBio Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the planned YouTube premiere, community viewings and educational programming; BridgeBio’s plans to support ATTR-CM education and awareness; and the potential benefits of greater awareness, earlier recognition and diagnosis of ATTR-CM. Although the Company believes that its plans, intentions and expectations as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that such plans, intentions or expectations will be attained or achieved. Actual results may differ materially from those described in the forward-looking statements due to a number of risks, uncertainties and assumptions, including those risks set forth in the Risk Factors section of the Company’s most recent Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected]
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
[email protected]

References
1. Attruby.com, “What Is ATTR-CM?” Disease overview and symptom information. Accessed January 27, 2026.
2. Attruby.com, “Signs & Symptoms” section. Accessed January 27, 2026.
3. Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(1):21-29. Accessed January 27, 2026.

BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a Bernstein discussion.

Trimarchi said the company’s strategy centers on developing medicines for genetic diseases with substantial unmet need, particularly where a genetic mechanism can be directly targeted. He also emphasized capital allocation discipline and net present value considerations as elements of BridgeBio’s operating model.

“We are here in this world to help as many patients living with genetic disease as we possibly can in the shortest amount of time,” Trimarchi said. Attruby Launch and New Evidence Trimarchi said Attruby, the company’s treatment for ATTR cardiomyopathy, is annualizing at more than $1 billion globally about six quarters after launch. BridgeBio expects the drug to reach global blockbuster status on a full-year basis by the end of the year, he said.

The company estimates that 15,000 to 16,000 patients annually are now reaching the “bottom of the funnel” in the ATTR cardiomyopathy market, compared with an estimated 8,000 patients two years earlier. Trimarchi said Attruby has about 25% share of new patient starts and that share is growing.

BridgeBio recently released real-world data comparing acoramidis, the active ingredient in Attruby, with tafamidis. According to Trimarchi, the analysis showed a 34% improvement for acoramidis on a composite measure of diuretic intensification, cardiovascular hospitalizations and all-cause mortality. He said the company also published data suggesting a kidney-protective effect, although the mechanism remains under investigation.

Julie Miller Everett, chief operating officer of BridgeBio’s Skeletal Dysplasias Business, said emerging evidence across the category has reinforced the company’s confidence in Attruby’s differentiation. BridgeBio continues to project more than $4 billion in peak-year sales for acoramidis.

Trimarchi said the company expects quarterly Attruby revenue increases of approximately $25 million to $30 million for the next several quarters, potentially through late 2027. He attributed the near-term pace partly to normalization in switches from tafamidis and to the changing mix between second-line and treatment-naive patients.

BridgeBio is also pursuing lifecycle-management efforts including the ACT-EARLY primary-prevention study in certain asymptomatic variant patients, a cardiac imaging study, further research into the renal findings and a once-daily formulation that Trimarchi said could enter the clinic within 12 to 18 months.

Rare-Disease Launches Ahead Among the company’s planned launches, BBP-418 is being developed for Limb-Girdle Muscular Dystrophy Type 2I/R9. Trimarchi described the condition as a progressive disease with no approved therapy, affecting an estimated 2,000 to 2,500 people in the U.S., approximately 5,000 in Europe, and another roughly 2,000 patients in Japan with related Fukuyama Muscular Dystrophy.

He said BBP-418’s Phase 3 trial showed statistically significant benefits versus placebo across measures including the North Star Ambulatory Assessment, forced vital capacity and a 10-meter walk test. BridgeBio expects an FDA decision on or before a Nov. 27, 2026, PDUFA date, according to Trimarchi. He said the company has identified about 500 U.S. patients with confirmed genotypes and mapped prescribers, which will form the initial launch pool.

BridgeBio also has encaleret under FDA review for autosomal dominant hypocalcemia type 1, or ADH1. Trimarchi said the therapy is designed to address activating mutations in the calcium-sensing receptor. In its Phase 3 study, more than 75% of patients discontinued conventional calcium and vitamin D therapy and achieved normal-range blood and urine calcium levels after six months, he said.

The drug has a May 8 PDUFA date, and BridgeBio has begun a Phase 3 study in postsurgical hypoparathyroidism. Trimarchi said the company expects to enroll that study next year and potentially report results from late 2027 to early 2028.

Infigratinib Targets Achondroplasia Miller Everett outlined BridgeBio’s planned launch approach for infigratinib in achondroplasia. She said the oral therapy directly targets the FGFR3 mutation associated with the condition, unlike currently available CNP analog treatments.

According to Miller Everett, infigratinib demonstrated statistically significant benefits in annualized height velocity and proportionality within 52 weeks. BridgeBio also presented data on otitis media, or ear infections, and sleep apnea, which she said showed benefits within 52 weeks.

She said only about 20% to 30% of U.S. families have opted for available treatment, compared with an estimated 70% to 80% outside the U.S. BridgeBio sees three potential sources of demand: untreated patients, patients seeking to move from injectable therapies, and patients who previously discontinued treatment.

BridgeBio has deployed medical personnel and is building commercial infrastructure in the U.S., while establishing country-specific commercialization models internationally. Trimarchi said the company sees the next 18 months as a period in which its four-product portfolio could support a broader, durable biopharmaceutical business.

About BridgeBio Pharma (NASDAQ:BBIO) BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and delivering medicines for patients with genetically driven diseases and cancers. Founded in 2015, the company operates through a group of subsidiary biotechnology businesses, each generally focused on a specific disease area or therapeutic program.

BridgeBio’s research and development activities span rare diseases, genetically defined cancers, cardiovascular conditions and other serious disorders.

BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

 | Source: BridgeBio Pharma, Inc.

PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on September 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 63,009 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected]
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
[email protected]

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 9,600 shares of the company’s stock, valued at approximately $715,000.

Several other hedge funds have also recently added to or reduced their stakes in BBIO. California State Teachers Retirement System grew its stake in shares of BridgeBio Pharma by 7,463.2% in the 2nd quarter. California State Teachers Retirement System now owns 12,532,377 shares of the company’s stock valued at $933,411,000 after purchasing an additional 12,366,674 shares during the period. Lionsbridge Wealth Management LLC bought a new position in shares of BridgeBio Pharma during the 2nd quarter worth approximately $704,000. Susquehanna Fundamental Investments LLC acquired a new stake in BridgeBio Pharma in the 2nd quarter valued at $289,000. Two Sigma Securities LLC acquired a new stake in BridgeBio Pharma in the 2nd quarter valued at $1,317,000. Finally, Harvey Capital Management Inc. acquired a new stake in BridgeBio Pharma in the 2nd quarter valued at $10,340,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Insider Transactions at BridgeBio Pharma In other news, CEO Neil Kumar sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $84.03, for a total transaction of $840,300.00. Following the transaction, the chief executive officer directly owned 505,686 shares in the company, valued at approximately $42,492,794.58. This represents a 1.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $80.06, for a total transaction of $160,120.00. Following the sale, the chief accounting officer directly owned 127,401 shares in the company, valued at $10,199,724.06. This trade represents a 1.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 257,103 shares of company stock worth $21,579,211. Corporate insiders own 14.23% of the company’s stock.

BridgeBio Pharma Stock Performance Shares of BBIO stock opened at $72.38 on Tuesday. BridgeBio Pharma, Inc. has a 52 week low of $48.78 and a 52 week high of $93.42. The stock has a market capitalization of $14.15 billion, a PE ratio of -20.27 and a beta of 0.97. The stock’s fifty day moving average is $80.54 and its 200-day moving average is $73.74. BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The company had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. The firm’s revenue was up 120.4% compared to the same quarter last year. During the same period last year, the company earned ($0.95) earnings per share. As a group, analysts forecast that BridgeBio Pharma, Inc. will post -2.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets BBIO has been the subject of several recent analyst reports. Truist Financial increased their price objective on BridgeBio Pharma from $102.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. JPMorgan Chase & Co. boosted their target price on shares of BridgeBio Pharma from $100.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 target price on shares of BridgeBio Pharma in a report on Thursday, September 10th. Wells Fargo & Company upped their target price on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Finally, UBS Group reiterated a “buy” rating on shares of BridgeBio Pharma in a research report on Wednesday, September 2nd. Twenty investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $102.61.

Read Our Latest Analysis on BBIO

(Free Report)

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and delivering medicines for patients with genetically driven diseases and cancers. Founded in 2015, the company operates through a group of subsidiary biotechnology businesses, each generally focused on a specific disease area or therapeutic program.

BridgeBio’s research and development activities span rare diseases, genetically defined cancers, cardiovascular conditions and other serious disorders.

Further Reading Five stocks we like better than BridgeBio Pharma Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings Institutional Money Is Pouring Into These 2 Altcoin ETFs The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares 3 Dividend Kings to Buy While They’re Still Beaten Down

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

BridgeBio pharma has delivered multiple clinical and commercial successes, yet shares have repeatedly sold off after positive catalysts. Infigratinib's dwarfism trial outperformed the market leader, and Attruby continues to beat sales estimates, with management now guiding higher peak sales. Recent competitor setbacks and new data on Attruby's kidney benefits and hospital day reduction further strengthen BBIO's commercial outlook.

A month has gone by since the last earnings report for BridgeBio Pharma (BBIO - Free Report) . Shares have lost about 10.7% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is BridgeBio Pharma due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for BridgeBio Pharma, Inc. before we dive into how investors and analysts have reacted as of late.

Q2 Earnings Miss, Sales Beat EstimatesBridgeBio reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents.

Revenues surged 120% year over year to $243.7 million, beating the Zacks Consensus Estimate of $222.6 million. This growth was primarily driven by Attruby.

Attruby Sales Drive the Top LineAttruby generated $222.4 million from product sales in the United States. The figure more than tripled from the $71.5 million recorded in the year-ago period.

Per BridgeBio, Attruby continued to gain share among treatment-naive patients, which management views as the key long-term growth driver for the franchise. Meanwhile, the pool of patients switching from Pfizer’s Vyndaqel/Vyndamax, a key competing ATTR-CM therapy, has begun to normalize after elevated switching activity in prior quarters. Management expects continued first-line share gains to support sales growth going forward.

Royalty revenues increased to $15.4 million from $1.6 million, primarily reflecting Attruby sales in the EU and Japan, where it is marketed as Beyonttra.

License and services revenues fell more than 84% year over year to $5.8 million, as the prior-year period benefited from a $30 million regulatory milestone.

Costs Rise on Commercial InvestmentsResearch and development expenses increased 34% year over year to $149.4 million, reflecting continued investment in late-stage programs.

Selling, general and administrative expenses climbed 44% to $186.3 million as the company supported Attruby commercialization and pre-commercial work for upcoming launches.

As of June 30, 2026, cash, cash equivalents and marketable securities totaled $720.2 million, down from $940.2 million in the previous quarter. The figure excludes the $1 billion preferred equity financing that closed July 1, which lifted the company's cash balance to about $1.7 billion.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates review.

The consensus estimate has shifted -18.21% due to these changes.

VGM ScoresAt this time, BridgeBio Pharma has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock has a score of F on the value side, putting it in the bottom 20% quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, BridgeBio Pharma has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerBridgeBio Pharma belongs to the Zacks Medical - Generic Drugs industry. Another stock from the same industry, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) , has gained 0.8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Teva Pharmaceutical Industries reported revenues of $4.14 billion in the last reported quarter, representing a year-over-year change of -0.8%. EPS of $0.02 for the same period compares with $0.66 a year ago.

For the current quarter, Teva Pharmaceutical Industries is expected to post earnings of $0.71 per share, indicating a change of -9% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.8% over the last 30 days.

Teva Pharmaceutical Industries has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.

Frazier Life Sciences Management L.P. decreased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 55.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,548,139 shares of the company’s stock after selling 1,900,000 shares during the period. BridgeBio Pharma makes up 2.5% of Frazier Life Sciences Management L.P.’s investment portfolio, making the stock its 11th largest holding. Frazier Life Sciences Management L.P. owned approximately 0.79% of BridgeBio Pharma worth $115,305,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Silvant Capital Management LLC bought a new stake in BridgeBio Pharma during the 2nd quarter valued at approximately $28,000. Allworth Financial LP bought a new position in shares of BridgeBio Pharma in the 2nd quarter worth approximately $31,000. Harvest Fund Management Co. Ltd purchased a new position in shares of BridgeBio Pharma in the 3rd quarter valued at approximately $34,000. Jones Financial Companies Lllp purchased a new position in shares of BridgeBio Pharma in the 1st quarter valued at approximately $35,000. Finally, Global Retirement Partners LLC boosted its position in shares of BridgeBio Pharma by 271.5% during the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock valued at $39,000 after purchasing an additional 372 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Wall Street Analyst Weigh In A number of equities analysts have issued reports on BBIO shares. TD Cowen increased their price objective on BridgeBio Pharma from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Truist Financial upped their target price on shares of BridgeBio Pharma from $102.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. JPMorgan Chase & Co. upped their target price on shares of BridgeBio Pharma from $100.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of BridgeBio Pharma in a research note on Wednesday, September 2nd. Finally, Raymond James Financial cut shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Twenty analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average target price of $101.53.

Get Our Latest Analysis on BridgeBio Pharma BridgeBio Pharma News Summary Here are the key news stories impacting BridgeBio Pharma this week:

Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $120 price target, indicating that the analyst believes BridgeBio’s longer-term growth potential remains intact despite the earnings-estimate reductions. HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma Positive Sentiment: Barclays and Cantor Fitzgerald also maintained Buy ratings on BridgeBio Pharma, providing additional analyst support for the stock. Barclays Sticks to Its Buy Rating for BridgeBio Pharma Cantor Fitzgerald Remains a Buy on BridgeBio Pharma Neutral Sentiment: HC Wainwright’s estimates still imply a transition from losses in 2026 to profitability in 2027, forecasting a $1.88 per-share loss for fiscal 2026 and $1.31 in earnings for fiscal 2027. Negative Sentiment: HC Wainwright lowered its fiscal 2026 EPS forecast to a $1.88 loss from a $1.50 loss and cut its fiscal 2027 estimate to $1.31 from $2.19. It also reduced estimates for several 2027 quarters, including Q1 to a $0.18 loss from $0.11 in earnings and Q2 to $0.19 in earnings from $0.44. Negative Sentiment: The estimate cuts extend to near-term results: Q3 2026 EPS was lowered to a $0.40 loss from a $0.38 loss, while Q4 2026 EPS was trimmed slightly to $0.13 from $0.14. These revisions may weigh on sentiment because they point to slower-than-previously-expected earnings progression. Insider Buying and Selling In related news, Director Andrea Ellis sold 17,167 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the sale, the director directly owned 22,579 shares of the company’s stock, valued at approximately $1,896,636. This represents a 43.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 2,808 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $68.00, for a total transaction of $190,944.00. Following the sale, the director owned 11,455 shares of the company’s stock, valued at approximately $778,940. This represents a 19.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 347,343 shares of company stock worth $27,591,000 over the last quarter. 14.23% of the stock is owned by insiders.

BridgeBio Pharma Stock Performance Shares of NASDAQ:BBIO opened at $74.84 on Monday. The stock has a fifty day simple moving average of $80.74 and a two-hundred day simple moving average of $73.61. BridgeBio Pharma, Inc. has a 12-month low of $48.78 and a 12-month high of $93.42. The stock has a market capitalization of $14.63 billion, a price-to-earnings ratio of -20.96 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analysts’ expectations of $220.91 million. During the same quarter in the prior year, the company posted ($0.95) earnings per share. The company’s revenue was up 120.4% on a year-over-year basis. As a group, equities research analysts predict that BridgeBio Pharma, Inc. will post -2.64 EPS for the current year.

BridgeBio Pharma Company Profile (Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

Featured Stories Five stocks we like better than BridgeBio Pharma AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Nine mid-sized drugmakers agreed to lower prescription drug prices under Trump's MFN pricing proposal.The companies committed at least $19.6 billion collectively to near-term U.S. manufacturing.The nine deals lift MFN coverage to 26 drugmakers, spanning 89% of the branded drug market. On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma (ALPMY - Free Report) , BeOne Medicines (ONC - Free Report) , BridgeBio Pharma (BBIO - Free Report) , CSL (CSLLY - Free Report) , Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals (TEVA - Free Report) and UCB (UCBJY - Free Report) .

Drug Pricing Deals Leave Some Details UnclearUnder the agreements, these companies agreed to reduce the prices of their prescription drugs to match those in comparable developed countries, as part of President Trump’s Most-Favored-Nation (“MFN”) pricing proposal. However, the announcement does not provide details on the drugs that will be covered or specify the exact size of the price reductions for individual medicines.

In return, each drugmaker will receive a reprieve from import tariffs on pharmaceutical ingredients, contingent upon expanding its domestic manufacturing operations. According to a White House disclosure, these nine companies are committed to investing at least $19.6 billion collectively in U.S. manufacturing in the near term.

New Pharma Deals Also Include API Supply CommitmentsSome of the participating drugmakers have also agreed to contribute active pharmaceutical ingredients (API) for key products to a government stockpile reserve called the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). The reserve is intended to reduce reliance on foreign suppliers and help ensure adequate supplies of critical medicines during emergencies.

In this connection, Astellas has agreed to contribute 25 kg of tacrolimus, which is used to help prevent organ rejection in people who have had organ transplants. In contrast, Teva will supply 45 metric tons of metronidazole, used to treat certain bacterial and parasitic infections, as well as 4.8 tons of amlodipine, a drug used to lower blood pressure.

Meanwhile, UCB has agreed to provide 163 tons of levetiracetam, which is used to control and prevent seizures, while Sun Pharma plans to contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline, antibiotics used to treat bacterial infections.

Trump’s MFN Push Now Covers 26 DrugmakersThe latest agreements build on the administration’s earlier push to secure MFN pricing from the industry’s largest pharmaceutical companies. Pfizer became the first drugmaker to sign such an agreement with the Trump administration in September 2025. This was followed by 16 other major pharmaceutical manufacturers, with Regeneron being the last to sign in April 2026.

With the addition of the nine mid-sized companies, the total number of drugmakers with MFN agreements has risen to 26. The White House said the agreements now cover 89% of the branded drug market.

Notably, the latest group is more geographically diverse than the first 17 companies, which were predominantly based in the United States and Europe. The new cohort includes Sun Pharma from India, Teva Pharmaceuticals from Israel, Astellas and Kyowa Kirin from Japan and CSL from Australia, broadening the reach of the administration’s MFN pricing campaign beyond its earlier focus.

Our Take: MFN Push Enters a New PhaseThe expansion to nine mid-sized drugmakers suggests that the administration’s MFN strategy is moving beyond its initial focus on Big Pharma and becoming a broader industry-wide pricing push. With 26 drugmakers now covered and the administration continuing to pursue additional agreements, the pressure on other manufacturers to strike similar deals could intensify in the coming months.

If this momentum continues, the policy could eventually move beyond voluntary agreements and toward a more permanent framework. The Trump administration has also called on Congress to codify its MFN agreements into law through the Great Healthcare Plan, potentially giving the policy a longer-term footing if enacted.

The timing of the latest agreements is notable, as the administration heads toward the November 2026 midterm elections. Continued announcements around lower drug prices could help reinforce the administration’s message on healthcare affordability, particularly as TrumpRx.gov has already become a key component of its drug-pricing strategy. The White House said the platform has generated more than $700 million in savings since its February launch, with GLP-1 drugs among the most prominent examples of discounted medicines.

 | Source: BridgeBio Pharma, Inc.

PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

21st Annual Wells Fargo Healthcare Conference, Boston, MA: Wednesday, September 9 at 1:30 pm EDT2026 Cantor Global Healthcare Conference, New York, NY: Thursday, September 10 at 9:10 am EDTMorgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Tuesday, September 15 at 10:00 am EDTBernstein Insights Healthcare Leaders and Disruptors 2026, New York, NY: Wednesday, September 23 at 9:40am EDT
To access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected] 
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
[email protected]

Key Takeaways BridgeBio's second-quarter 2026 revenues jumped 120%, driven by rapid growth in Attruby sales.Three potential U.S. launches could broaden BBIO's revenue base over the next 12 months.BBIO trades at a 11.96 EV-to-sales ratio, well above its comparison groups. BridgeBio Pharma (BBIO - Free Report) is entering a pivotal commercial stretch. Attruby is scaling quickly, while three late-stage candidates could widen the company’s revenue base over the next year.

The trade-off is a demanding valuation alongside continued losses, product concentration and launch risk. The investment case therefore depends on whether commercial expansion can justify BBIO’s premium to its comparison groups.

BBIO’s Growth Case Starts With AttrubySecond-quarter 2026 revenues jumped 120% year over year to $243.7 million, topping the Zacks Consensus Estimate of $222.6 million. Attruby generated $222.4 million in U.S. product sales, more than triple the $71.5 million reported a year earlier.

Attruby’s first-half 2026 U.S. sales reached $403 million. The Zacks Consensus Estimate calls for 2026 revenues of $1,008 million, while BridgeBio estimates that diagnosed U.S. ATTR-CM patients increased from fewer than 5,000 in 2019 to more than 50,000 in 2025. The expanding diagnosed population supports Attruby’s commercial opportunity.

BridgeBio’s Pipeline Could Broaden Revenue SourcesBridgeBio is preparing for three potential U.S. product launches over the next 12 months. BBP-418 is under FDA review for limb-girdle muscular dystrophy type 2I/R9, with a decision expected by Nov. 27, 2026. If approved, it could become the first therapy for this patient population.

Encaleret is under review for autosomal dominant hypocalcemia type 1, with an FDA decision expected by May 8, 2027. BridgeBio also submitted infigratinib for achondroplasia in the third quarter of 2026 and is targeting a potential launch in early to mid-2027. A $1 billion preferred equity financing closed July 1 to support current and planned launches.

BBIO’s Valuation Demands Strong ExecutionBBIO trades at a forward 12-month enterprise-value-to-sales ratio of 11.96 versus 2.87 for the Zacks sub-industry, 2.58 for the Zacks Medical sector and 4.84 for the S&P 500. Shares have gained 24% in the past three months and 71.4% in the past year.

The current multiple is below BBIO’s five-year median of 34.62, but the gap versus broader comparison groups remains substantial. That premium makes regulatory delays, slower product uptake or weaker-than-expected Attruby share gains more consequential for investors.

BridgeBio Still Faces Concentration and Launch RisksAttruby remains BridgeBio’s only approved commercial product. Pfizer Inc. (PFE - Free Report) continues to market Vyndamax for ATTR-CM, while Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) has Amvuttra approved for ATTR-CM. BridgeBio said Attruby’s estimated frontline share rose two to three percentage points in the second quarter, but payer access and continued clinical differentiation remain important for further gains.

Execution risk extends beyond Attruby. BridgeBio must build physician awareness, identify eligible patients and secure reimbursement for potential new products. The company also reported a second-quarter loss of 78 cents per share versus the consensus loss estimate of 64 cents, while research and development expenses rose 34% and selling, general and administrative expenses increased 44%.

BBIO’s Style Scores Favor Growth Over ValueThe balance of rapid sales expansion, a broader potential product base and a steep relative valuation supports a measured stance rather than an aggressive directional call. Commercial progress could strengthen the case, but regulatory and launch execution remain central to the outlook.

BBIO currently carries a Zacks Rank #3 (Hold), which supports a measured posture. Its Growth Score of B indicates relatively favorable growth characteristics. By contrast, its Value Score of F and Momentum Score of D point to weaker valuation and momentum characteristics, while its VGM Score of D shows that the combined style profile is not broadly favorable. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways BridgeBio's Q2 revenue reached $243.7 million, led by Attruby's $222.4 million in U.S. sales.Attruby's first-line share gained two to three points as patient switching from Pfizer normalized.BridgeBio had about $1.7 billion in cash after a July financing, supporting three potential launches. BridgeBio Pharma (BBIO - Free Report) entered the second half of 2026 with Attruby doing most of the commercial heavy lifting. Second-quarter revenues rose 120% year over year and topped the Zacks Consensus Estimate, but the company still posted a wider-than-expected loss as development and launch spending increased.

That split matters for investors. Attruby is scaling quickly while BridgeBio funds several late-stage programs and potential launches. The question for the rest of 2026 is whether first-line ATTR-CM share gains can keep revenue momentum moving.

BBIO’s Q2 Sales Beat Came From AttrubySecond-quarter revenues reached $243.7 million, above the Zacks Consensus Estimate of $222.6 million. Attruby generated $222.4 million in U.S. product sales, more than tripling from $71.5 million a year earlier and accounting for most of the quarter's top line.

Royalty revenues rose to $15.4 million from $1.6 million, mainly on Beyonttra sales in the European Union and Japan. License and services revenues fell more than 84% to $5.8 million because the year-earlier period included a $30 million regulatory milestone.

BridgeBio’s Loss Shows the Cost of ExpansionBridgeBio lost 78 cents per share, wider than the Zacks Consensus Estimate of a 64-cent loss, though the result improved from a 95-cent loss a year earlier. Revenue growth has not yet translated into profitability.

Research and development expenses increased 34% to $149.4 million as BridgeBio invested in late-stage programs. Selling, general and administrative expenses climbed 44% to $186.3 million as the company supported Attruby commercialization and pre-commercial work for upcoming launches.

BBIO’s First-Line Share Gains Matter for 2026Management sees treatment-naive patients as Attruby's key long-term growth source. The pool of patients switching from Pfizer's Vyndaqel/Vyndamax has begun to normalize after elevated activity in prior quarters. BridgeBio estimated that Attruby's first-line share rose two to three percentage points in the second quarter.

Pfizer Inc. (PFE - Free Report) competes through its Vyndaqel family, the therapy from which some Attruby patients have switched. Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) adds another ATTR-CM competitor through Amvuttra. Sustained first-line gains therefore matter as switching provides less incremental support.

BridgeBio’s Cash Position Supports More LaunchesBridgeBio ended June with $720.2 million of cash, cash equivalents and marketable securities, down from $940.2 million at the end of the prior quarter. That figure excluded the $1 billion preferred equity financing that closed July 1 and lifted the cash balance to about $1.7 billion.

The added liquidity supports a period in which BridgeBio is preparing for three potential U.S. product launches over the next 12 months. BBP-418 has an FDA decision date of Nov. 27, 2026. Encaleret is under review for a May 8, 2027 decision, while infigratinib is targeted for a potential early- to mid-2027 launch if approved.

BBIO’s Ratings Reflect Growth With Execution RiskThe bottom line is that commercial momentum is clear, but earnings pressure remains. Attruby delivered the sales beat, while BridgeBio continues to absorb high development and commercialization costs and relies heavily on one marketed product.

BBIO currently carries a Zacks Rank #3 (Hold). Within the Style Score framework, a #3 Rank sits between the stronger #1 (Strong Buy) and #2 (Buy) categories and the weaker #4 (Sell) and #5 (Strong Sell) categories. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Growth Score of B is BBIO's strongest style signal, while the Momentum Score of D and Value Score of F are less favorable. Its VGM Score of D points to a mixed combined profile as BridgeBio works to sustain Attruby growth and execute on its launch pipeline.

 | Source: BridgeBio Pharma, Inc.

- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing clinically meaningful improvement in cardiac function in the completer analysis

- Patients treated with acoramidis were observed to have an unprecedented 65 additional days alive and out of the hospital by Month 36 versus baseline placebo patients

- Acoramidis demonstrated long-term efficacy and safety through 54 months across variant ATTR-CM subgroups, including p.Val142Ile and non-p.Val142Ile. These findings were simultaneously published in the European Journal of Heart Failure

PALO ALTO, Calif., Aug. 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, presented new analyses from the Phase 3 ATTRibute-CM study of Attruby® (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR-CM), including the cardiac magnetic resonance imaging (CMR) substudy and the open-label extension (OLE) at the European Society of Cardiology (ESC) Congress 2026. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

“The clinical community is excited about the potential to restore heart health found in these data. For a long time, patients living with ATTR-CM could only hope for a stop to the otherwise relentless progression of disease. These new CMR data from ATTRibute-CM shows evidence of reversal in a meaningful proportion of individuals treated with acoramidis, with roughly half showing improved left ventricular systolic function in the completer analysis, more than 2x the proportion observed in the natural history from a NAC cohort or in ATTRibute-CM participants treated with placebo. These findings support acoramidis as a therapy capable of altering the trajectory of this otherwise progressive disease,” said Marianna Fontana, M.D. of University College London, UK. “For patients and clinicians navigating ATTR-CM, this is an exciting signal that the treatment paradigm is shifting toward a therapy that could actively restore heart health rather than only manage decline.”

The CMR substudy of ATTRibute-CM and its open-label extension provide the first evidence from serial CMR that a therapy can potentially reverse disease progression through Month 42. The findings presented by Awais Sheikh, MBChB of the National Amyloidosis Centre, London, UK were evaluated using two complementary analytical approaches, which found:

In a completer analysis, clinically meaningful improvement from baseline in left ventricular (LV) systolic function was observed in 54% of acoramidis-treated patients versus 20% of placebo-treated patients at Month 30, and in 53% of continuous-acoramidis patients at Month 42For context, only 26% of completers in an independent natural history cohort demonstrated improved LV systolic function by Month 24 – approximately half the rate observed with acoramidis, suggesting that this magnitude of improvement falls outside the expected natural course of diseaseIn a conservative analysis, long-term acoramidis treatment was associated with clinically meaningful improvement from baseline in LV systolic function in approximately one-third of patients over 30-42 months. Improvement was observed in 34% of acoramidis-treated patients versus 9% of placebo-treated patients at Month 30 and in 30% of continuous-acoramidis patients at Month 42In addition, 46% of patients receiving continuous acoramidis demonstrated improvement from baseline in LV mass index at Month 42, providing evidence of favorable structural remodelingThese results provided sufficient evidence for BridgeBio to recently dose its first participant in ASCEND-ATTR, a Phase 3b/4 study designed to determine if acoramidis is associated with sustained improvement in myocardial structural disease progression, function and amyloid burden In a post-hoc analysis of ATTRibute-CM presented by Richard Wright, M.D. of the Pacific Heart Institute, U.S., acoramidis preserved significantly more time alive outside the hospital for patients with ATTR-CM. The analysis evaluated days lost to death and/or cardiovascular-related hospitalization (DLDCVH), a patient-centered measure that integrates all-cause mortality, cardiovascular-related hospitalizations, and length of stay into a single assessment of disease burden. Key findings included:

In participants with ATTR-CM, acoramidis reduced the estimated mean percentage of DLDCVH to 7.5% versus 11.7% with placebo through Month 30Acoramidis preserved more than one month of additional time alive and out of the hospital (38 days) over 30 months with the benefit nearly doubling to 65 days (observed) over three years, and nearly tripling to up to 94 days (modelled estimates) over three years, reflecting progressive divergence in outcomes over time The p.Val142Ile genetic variant is the most common ATTR-CM genetic variant globally, disproportionately affecting individuals of Western African ancestry, with a carrier frequency of 3-4% in the U.S. Black population. Findings in the ATTRibute-CM OLE presented by Kevin Alexander, M.D. of Stanford University School of Medicine, U.S. showed continued benefit of acoramidis in 56 variant ATTR-CM (ATTRv-CM) patients, including 35 p.Val142Ile and 21 non-p.Val142Ile patients through Month 54, demonstrating:

All-cause mortality (ACM) and cardiovascular mortality (CVM) were markedly lower in the continuous acoramidis arm versus placebo-to-acoramidis across both p.Val142Ile and non-p.Val142Ile variant subgroupsThrough Month 54, ACM was 30.4% with continuous acoramidis versus 66.7% with placebo-to-acoramidis in the p.Val142Ile subgroup, and 24.3% with continuous acoramidis versus 57.9% with placebo-to-acoramidis across the overall ATTRv-CM population, a consistent, more than two-fold difference in mortality favoring continuous treatmentThe ACM and CVM rates at Month 54 were notably high (~65%) in the p.Val142Ile group who were randomized to placebo in ATTRibute-CM, underscoring the substantial unmet medical need in this high-risk subgroupContinuous acoramidis achieved sustained increases in serum TTR (sTTR) and persistent attenuation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) rise through Month 54 in both participants with p.Val142Ile or non-p.Val142Ile variantsThese Month 54 findings extend the survival benefit and favorable biomarker trends previously reported at Month 30, demonstrating the long-term durability of efficacy and safety of acoramidis in ATTRv-CM, including in the p.Val142Ile subgroupAcoramidis remained well tolerated through Month 54, with no new safety signals observed in the OLE In addition to the one oral presentation and two moderated posters highlighted, two additional moderated posters on acoramidis were shared at the ESC Congress 2026, including:

Acoramidis Improves Health-Related Quality of Life in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: An EQ-5D-5L Subgroup Analysis from ATTRibute-CM, presented by Emer Joyce, M.D., Ph.D. of The Mater Misericordiae University Hospital, IE Treatment with acoramidis resulted in significant and clinically meaningful benefits in health-related quality of life (HRQoL) in both wild-type ATTR-CM (ATTRwt-CM) and ATTRv-CM. Greater impact on HRQoL versus placebo was observed in participants with ATTRv-CM Improvement of Health Status with Acoramidis in Patients with Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: KCCQ Domains Analysis from the ATTRibute-CM Study, presented by Nitasha Sarswat, M.D. of University of Chicago Medical Center, U.S. In ATTRibute-CM, acoramidis attenuated the decline in heart failure-related health status versus placebo in participants with ATTRwt-CM and ATTRv-CM, with consistent benefits observed across Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) and individual domain scores. A numerical improvement was observed across almost all KCCQ domains in acoramidis-treated participants with ATTRwt-CM and ATTRv-CM relative to placebo As part of BridgeBio's partnership with Yale's Cardiovascular Data Science (CarDS) Lab to advance AI networks for earlier detection of ATTR-CM, three posters were presented at the ESC Congress 2026. Findings from the partnership included:

A Novel AI-Derived Digital Biomarker for Monitoring Disease Progression in ATTR-CM: First-In-Trial Use of a Computer Vision AI-ECG Algorithm within a Phase 3 Pivotal Randomized Controlled Trial, presented by Rohan Khera, M.D. of Yale School of Medicine, U.S. This showed the first deployment of a computer vision AI-ECG algorithm, operating directly on ECG data, as a digital biomarker in a RCT (ATTRibute-CM). An image-based AI-ECG algorithm demonstrated discrimination across clinical subgroups at baseline and detected differential longitudinal changes between acoramidis and placebo over 30 months. These findings support the potential role of AI-ECG derived prediction scores as a scalable digital biomarker in clinical trials and potential routine cardiovascular care A Fully Decentralized, Patient-Led Digital Registry for ATTR-CM Integrating Multisystem EHR and Wearable Data: The DISCOVER-ATTR Study, presented by Aline Pedroso, Ph.D. of Yale School of Medicine A fully decentralized, patient-led digital registry can successfully aggregate longitudinal multisystem electronic health records (EHR) data and wearable physiologic signals in ATTR-CM. Early results show substantial data yield and feasibility of longitudinal mapping of care trajectories and multimodal risk prediction, providing a blueprint for next-generation registries in rare cardiovascular diseases Nationwide U.S. Federated Deployment of Artificial Intelligence for Multimodal Screening of ATTR Cardiomyopathy: First Multicenter Analysis from the TRACE-AI Network, presented by Bruno Batinica, MBChB of Yale School of Medicine In this largest-ever deployment of AI-electrocardiogram and AI-Echo models for opportunistic retrospective screening of individuals at risk of ATTR-CM, we demonstrate a large burden of probable undiagnosed ATTR-CM with prognostic implications. Leveraging this framework for screening holds promise for enabling broad, timely identification of patients to maximize the overall benefit of new therapies Acoramidis is approved as Attruby® by the U.S. FDA and is approved as BEYONTTRA® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, and the Brazilian Health Regulatory Agency (ANVISA) with all labels specifying near-complete stabilization of TTR.

Additional data on the benefit of Attruby for individuals with ATTR-CM is planned for future medical meetings, including Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, taking place in Phoenix, Arizona on October 9-12, 2026.

About Attruby® (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the data presented regarding acoramidis, including the potential clinical and therapeutic implications of observed changes in cardiac structure and function and the potential for acoramidis to alter the trajectory of ATTR-CM and restore heart health; the potential utility of AI-based tools and digital biomarkers for the detection, monitoring and screening of ATTR-CM in clinical trials and clinical practice; and BridgeBio’s plans to present additional data regarding Attruby at future medical meetings. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data, the design and success of ongoing and planned clinical trials, the risk that results from post hoc analyses, subgroup analyses or other analyses may not be predictive of future clinical outcomes or treatment effects, that observed improvements in cardiac structure, function or other measures may not be replicated in additional analyses or studies or translate into improved long-term clinical outcomes, that the potential utility of AI-based tools and digital biomarkers may not be demonstrated in further studies or translate into routine clinical use, that plans to present additional data may change, the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected]
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
[email protected]

One of the more high-flying stocks in the U.S. biotech sector these days is genetic-disease-focused BridgeBio Pharma (BBIO -1.18%). That's due almost entirely to the outperformance of its Attruby heart medication.

If the generally bullish analyst sentiment on the company is anything to go by, Attruby is only at the start of a long, successful run. Also, BridgeBio is well on track to succeed with pipeline drugs in the near future.

Image source: Getty Images.

A new and popular treatment
Attruby received U.S. Food and Drug Administration (FDA) approval in late 2024 for the treatment of a rare progressive heart disease called transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a type of cardiac amyloidosis.

The drug is a state-of-the-art treatment for ATTR-CM and as such has seen significant growth in its short commercial life. In its recent second-quarter earnings report, BridgeBio disclosed that Attruby sales more than tripled year over year, to more than $222 million from $71.5 million in the year-ago period (its first full quarter on the market).

Since Attruby is far and away the primary contributor to overall revenue -- it's the only commercialized product currently producing sales -- BridgeBio's top line expanded admirably. Its total second-quarter tally was nearly $244 million, more than double the nearly $111 million in the second quarter of 2025.

The company also boasts quite a promising drug pipeline. In that recently completed quarter, it submitted New Drug Applications (NDAs) for all three of its late-stage developmental programs to the FDA; two were accepted for review.

The trio consists of the muscular dystrophy treatment BBP-418; encaleret, which targets a rare endocrine disorder, autosomal dominant hypocalcemia; and infigratinib, a drug that treats a form of short-stature skeletal dysplasia (commonly referred to as dwarfism).

Today's Change

(

-1.18

%) $

-0.96

Current Price

$

80.25

The power of the pipeline
That combination of a relatively new medication on a sharp rise and a lineup of high-potential drugs now under review is impressing analysts.

Following the earnings release, Piper Sandler's Biren Amin, to name one, raised his price target on the stock while maintaining his "overweight" (buy) recommendation. He believes the one developmental drug under review that's received a 2026 Prescription Drug User Fee Act (PDUFA) review date from the FDA, BBP-418, will earn approval and start generating revenue by the end of this year. Its PDUFA decision date is Nov. 27.

According to analyst tracking site TipRanks, 16 out of 17 pundits currently following BridgeBio's fortunes recommend it as a buy, with only one rating it a hold. Personally, I find that realistic. I'd go so far as to say that BridgeBio currently has one of the best combinations of a commercialized anchor drug and advanced developmental programs in the biotech sector.

That doesn't mean it's perfect, of course -- the company remains unprofitable. That's understandable, though, given the resources needed to support both the commercialization of Attruby and the late-stage development of three other drugs.

But to my mind, if any investor with some risk appetite is going to take a chance on a biotech, BridgeBio is a fine choice. Like most of those analysts, I think the stock can gain even more altitude.

PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering.

PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 56 new employees in restricted stock units for an aggregate of 66,705 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

Key Takeaways Vertex Pharmaceuticals awaits a Nov. 30 FDA decision on povetacicept filing for IgA nephropathy.Amylyx expects third-quarter 2026 phase III LUCIDITY results for avexitide in post-bariatric hypoglycemia.Praxis expects an FDA decision on relutrigine for DEEs by Dec. 27, followed by EMERALD study data in Q4. The pharmaceutical sector differs from many industries as stock performance often depends less on near-term results and more on the success of products in development. For biotech companies, clinical and regulatory developments can sharply alter valuations by changing expectations for a drug's safety, efficacy and commercial potential.

Pipeline milestones are therefore key stock catalysts. Clinical data can validate or undermine a candidate, while regulatory decisions can bring it closer to commercialization. Late-stage data and regulatory milestones generally have a significant impact on stock prices as they offer more clarity on a drug's approval prospects.

Against this backdrop, Vertex Pharmaceuticals (VRTX - Free Report) , Amylyx Pharmaceuticals (AMLX - Free Report) , Praxis Precision Medicines (PRAX - Free Report) and BridgeBio Pharma (BBIO - Free Report) stand out for having notable pipeline/regulatory developments during the second half of 2026. With multiple clinical and regulatory milestones spanning pain, metabolic disorders, neurological diseases and rare genetic conditions, these companies offer several potentially meaningful catalysts, making the four biotech stocks particularly compelling investment opportunities.

Vertex PharmaceuticalsThe key near-term catalyst for Vertex is the FDA’s pending decision on a biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy (IgAN), scheduled for Nov. 30, 2026. Acquired from Alpine Immune Sciences, povetacicept is being developed as a potential best-in-class therapy for multiple B-cell-mediated diseases and could help Vertex expand beyond its established cystic fibrosis franchise.

Year to date, VRTX shares have gained 15.6% compared with the industry’s 5.2% growth.

Image Source: Zacks Investment Research

The upcoming FDA decision could be particularly important given povetacicept’s potential role in establishing Vertex’s presence in nephrology. If approved, povetacicept would become Vertex’s first commercialized therapy in nephrology, creating a potential new source of product revenues and growth. The company is also advancing povetacicept in primary membranous nephropathy, another B-cell-mediated disease, and has completed the phase IIB portion of the mid- to late-stage program. Conversely, a regulatory setback could delay the candidate’s commercial prospects and weaken expectations for its contribution to Vertex’s longer-term growth. VRTX currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Amylyx PharmaceuticalsAmylyx's lead candidate, avexitide, a GLP-1 receptor antagonist, is being developed for post-bariatric hypoglycemia, a condition for which there are currently no FDA-approved therapies. The key near-term catalyst is top-line results from the phase III LUCIDITY study, which Amylyx expects to report in the third quarter of 2026. The study has completed enrollment, with its primary endpoint being the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16.

Year to date, AMLX shares have soared 87.6% against the industry’s 1.5% decline.

Image Source: Zacks Investment Research

The upcoming readout could be particularly important given avexitide’s central role in Amylyx’s pipeline. Earlier clinical studies have demonstrated consistent, dose-dependent effects, providing a supportive backdrop ahead of the pivotal readout. If the phase III study is successful and avexitide is subsequently approved, Amylyx aims to launch the drug commercially in 2027. This would give the company its first marketed drug and a potential recurring source of product revenues, making the LUCIDITY outcome a significant inflection point. Conversely, an unfavorable result could materially weaken avexitide’s regulatory and commercial prospects. Amylyx is also exploring avexitide in congenital hyperinsulinism. AMLX currently carries a Zacks Rank #3.

Praxis Precision MedicinesA potential FDA approval for relutrigine in genetically defined developmental epileptic encephalopathies (DEEs) is Praxis' most prominent second-half catalyst. The new drug application (NDA) is supported by positive results from the registrational cohort of the phase II/III EMBOLD study, which met its primary efficacy objective, demonstrating a 53% placebo-adjusted reduction in monthly motor seizures over 16 weeks in patients with SCN2A- and SCN8A-related DEEs. Although the drug initially received priority review with a Sept. 27, 2026, decision date, the FDA extended the review period by three months, establishing a new Dec. 27, 2026, target action date. The mid-cycle meeting was completed without major safety or efficacy concerns identified to date, and no advisory committee meeting is planned.

Year to date, PRAX shares have rallied 24.6% compared with the industry’s 5.3% growth.

Image Source: Zacks Investment Research

The catalyst is not limited to the regulatory decision. The EMERALD study, evaluating relutrigine in patients with broader DEEs, has completed recruitment and is expected to report top-line results in the fourth quarter of 2026. If positive, the study could support a supplemental NDA in 2027, potentially expanding the commercial opportunity beyond the genetically defined SCN2A- and SCN8A-DEE populations covered by the initial application. PRAX currently carries a Zacks Rank #3.

BridgeBio PharmaFDA action on BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) represents BridgeBio's major second-half catalyst. BBP-418 is an investigational oral glycosylation substrate therapy with a unique mechanism of action that could improve muscle, ambulatory and cardiopulmonary function. Its differentiated proposition is particularly notable because, if approved, BBP-418 could become the first and only approved therapy for LGMD2I/R9 and potentially the first approved therapy for any form of limb-girdle muscular dystrophy.

Year to date, BridgeBioshares have gained 10.7% compared with the industry’s 6.8% growth.

Image Source: Zacks Investment Research

The candidate has already cleared a major clinical hurdle. In the phase III FORTIFY study, BBP-418 met all primary and secondary endpoints at the prespecified 12-month interim analysis, with treated participants improving while placebo recipients declined across key measures. The FDA subsequently accepted BridgeBio's NDA for Priority Review and assigned a decision date of Nov. 27, 2026. The agency is not currently planning an advisory committee meeting, further focusing attention on the regulatory decision itself. BridgeBio also intends to initiate studies in younger LGMD2I/R9 patients and in additional LGMD subtypes, providing potential avenues for label expansion if the initial regulatory outcome is favorable. BBIO currently carries a Zacks Rank #3.

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO - Free Report) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -21.88%. A quarter ago, it was expected that this rare disease drug developer would post a loss of $0.7 per share when it actually produced a loss of $0.84, delivering a surprise of -20%.

Over the last four quarters, the company has not been able to surpass consensus EPS estimates.

BridgeBio Pharma, which belongs to the Zacks Medical - Generic Drugs industry, posted revenues of $243.68 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 9.46%. This compares to year-ago revenues of $110.57 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

BridgeBio Pharma shares have added about 10.5% since the beginning of the year versus the S&P 500's gain of 13.3%.

What's Next for BridgeBio Pharma?While BridgeBio Pharma has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for BridgeBio Pharma was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.57 on $249.98 million in revenues for the coming quarter and -$2.31 on $965.61 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Generic Drugs is currently in the bottom 12% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Assembly Biosciences (ASMB - Free Report) , is yet to report results for the quarter ended June 2026.

This biotech drug developer is expected to post quarterly loss of $0.70 per share in its upcoming report, which represents a year-over-year change of +47.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Assembly Biosciences' revenues are expected to be $9.2 million, down 4.5% from the year-ago quarter.

PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

BridgeBio Pharma (BBIO - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis rare disease drug developer is expected to post quarterly loss of $0.63 per share in its upcoming report, which represents a year-over-year change of +33.7%.

Revenues are expected to be $223.36 million, up 102% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.53% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for BridgeBio Pharma?For BridgeBio Pharma, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +13.69%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that BridgeBio Pharma will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that BridgeBio Pharma would post a loss of$0.7 per share when it actually produced a loss of -$0.84, delivering a surprise of -20.00%.

The company has not been able to beat consensus EPS estimates in any of the last four quarters.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

BridgeBio Pharma appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Posted by Defense World Staff on Jul 24th, 2026

California Public Employees Retirement System raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 21.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 253,479 shares of the company’s stock after acquiring an additional 45,596 shares during the period. California Public Employees Retirement System owned 0.13% of BridgeBio Pharma worth $18,823,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Global Retirement Partners LLC grew its position in shares of BridgeBio Pharma by 271.5% in the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock valued at $39,000 after purchasing an additional 372 shares during the period. Farther Finance Advisors LLC lifted its position in BridgeBio Pharma by 91.4% during the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after buying an additional 245 shares during the period. Kemnay Advisory Services Inc. purchased a new position in BridgeBio Pharma during the fourth quarter worth about $41,000. Cary Street Partners Investment Advisory LLC boosted its stake in BridgeBio Pharma by 861.0% in the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 567 shares of the company’s stock worth $43,000 after buying an additional 508 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in BridgeBio Pharma in the 4th quarter worth about $44,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Insider Activity In related news, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $67.46, for a total transaction of $2,698,400.00. Following the transaction, the chief executive officer owned 535,686 shares in the company, valued at approximately $36,137,377.56. The trade was a 6.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Thomas Trimarchi sold 13,651 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $65.08, for a total value of $888,407.08. Following the completion of the sale, the chief financial officer directly owned 359,194 shares of the company’s stock, valued at $23,376,345.52. The trade was a 3.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 432,117 shares of company stock valued at $32,633,740 over the last quarter. 14.23% of the stock is owned by insiders.

BridgeBio Pharma Price Performance Shares of NASDAQ:BBIO opened at $82.93 on Friday. The business has a 50-day moving average of $72.33 and a two-hundred day moving average of $72.45. The firm has a market capitalization of $16.24 billion, a PE ratio of -22.17 and a beta of 0.95. BridgeBio Pharma, Inc. has a 12 month low of $42.09 and a 12 month high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.51 million during the quarter, compared to analyst estimates of $178.07 million. BridgeBio Pharma’s quarterly revenue was up 66.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.88) earnings per share. As a group, research analysts anticipate that BridgeBio Pharma, Inc. will post -2.29 earnings per share for the current year.

Analyst Ratings Changes Several analysts have commented on BBIO shares. HC Wainwright lifted their price target on BridgeBio Pharma from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, July 13th. Weiss Ratings reissued a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Royal Bank Of Canada assumed coverage on shares of BridgeBio Pharma in a research report on Thursday, April 9th. They issued an “outperform” rating and a $100.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of BridgeBio Pharma in a report on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 target price for the company. Finally, Truist Financial upped their price target on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Twenty analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $95.21.

View Our Latest Report on BridgeBio Pharma

BridgeBio Pharma Profile (Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

Further Reading Five stocks we like better than BridgeBio Pharma Premium Retail’s Stress Test Is Separating Winners From Losers D-Wave Quantum or a Quantum ETF: Which Is the Better Bet? GE Vernova Just Sent a Mixed AI Signal to Investors Alphabet Crushed Earnings, But One Number Spooked the Market

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Raises Stake in Autoliv, Inc. $ALV

NEXT HEADLINE »Toast, Inc. $TOST Shares Sold by California Public Employees Retirement System